Switch to: References

Add citations

You must login to add citations.
  1. Research With Controlled Drugs: Why and Why Not? Response to Open Peer Commentaries on “An Ethical Exploration of Barriers to Research on Controlled Drugs”.Michael H. Andreae, Evelyn Rhodes, Tyler Bourgoise, George M. Carter, Robert S. White, Debbie Indyk, Henry Sacks & Rosamond Rhodes - 2016 - American Journal of Bioethics 16 (4):1-3.
    We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of legal consequences, stigma associated with abuse and populations using illicit drugs, and lack of funding may, however, limit research on their considerable therapeutic potential. We review (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Ethics and ego dissolution: the case of psilocybin.William R. Smith & Dominic Sisti - 2021 - Journal of Medical Ethics 47 (12):807-814.
    Despite the fact that psychedelics were proscribed from medical research half a century ago, recent, early-phase trials on psychedelics have suggested that they bring novel benefits to patients in the treatment of several mental and substance use disorders. When beneficial, the psychedelic experience is characterized by features unlike those of other psychiatric and medical treatments. These include senses of losing self-importance, ineffable knowledge, feelings of unity and connection with others and encountering ‘deep’ reality or God. In addition to symptom relief, (...)
    Download  
     
    Export citation  
     
    Bookmark   21 citations